Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 3/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135732 | 0.96 | ITK (0.35) | ITKSYKBRAFABL1CHEK2 | |
| SCHEMBL4128962 | 0.94 | ITK (0.36) | ITKSYKBRAFABL1 | |
| SCHEMBL18833146 | 0.92 | SYK (0.38) | ITKSYKBRAFABL1CHEK2 | |
| SCHEMBL4145845 | 0.92 | BRAF (0.34) | ITKSYKBRAFABL1CHEK2 | |
| SCHEMBL3928248 | 0.92 | SYK (0.44) | ITKSYKBRAFABL1CHEK2 | |
| SCHEMBL4129940 | 0.91 | SYK (0.39) | ITKSYKBRAFABL1CHEK2 | |
| SCHEMBL4145423 | 0.90 | BRAF (0.33) | ITKSYKBRAFABL1AXL | |
| SCHEMBL4129683 | 0.90 | SYK (0.34) | ITKSYKBRAFABL1CHEK2 | |
| SCHEMBL4129592 | 0.89 | AURKA (0.35) | ITKSYKBRAFABL1CHEK2 | |
| SCHEMBL4130187 | 0.89 | SYK (0.35) | ITKSYKBRAFABL1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041119-B1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2017-05-10 | — | — | EP | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | RB1, CCNI, CDK2 | ITK 1817/4885SYK 392/4885BRAF 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.